Feb 22, 2022
Arthrosi Welcomes New Chief Financial Officer
Arthrosi announced the appointment of Philip Moody as its Chief Financial Officer, who brings more than 25 years of experience and a track record of success working in private and public biotech companies.
Read MoreDec 14, 2021
Arthrosi Therapeutics, Inc. Announces Patient Enrollment in Global Phase 2b Study of AR882
Arthrosi announced today patient enrollment in a global phase 2b study of AR882, its novel drug candidate. AR882 is a new uricosuric agent in clinical development for the management of hyperuricemia in patients with gout, including patients with chronic, refractory tophaceous gout.
Read MoreNov 02, 2021
Arthrosi Presents AR882 Posters at ACR 2021
Arthrosi Therapeutics, Inc., a clinical-stage biotech company announced results from its renal impairment studies and human AME study.
Read MoreOct 12, 2021
Arthrosi Appoints Robert Thomas Keenan MD, MPH, MBA as Chief Medical Officer
Dr. Keenan has spent nearly 20 years in the field of rheumatology, bringing his vast expertise to the team as they reach Phase2b in the clinical development of the next generation molecule for the treatment of gout.
Read MoreAug 17, 2021
Arthrosi Establishes Joint Venture in China to Accelerate Development of Innovative Drug Portfolio
Arthrosi Therapeutics, Inc. today announced a joint venture in Guangzhou China with Ruiao Biopharmaceutical Technology Co., Ltd. ("a subsidiary of ApicHope Phamaceutical") to form Guangzhou Ruianbo Pharmaceutical Technology Co., Ltd.
Read MoreJun 01, 2021
Arthrosi Therapeutics, Inc. Announces Impressive Phase 2a Study Results
With AR882 showing strong efficacy and safety profile in Phase 2a study, Arthrosi is accelerating the development and looking to complete the Phase 2 studies by the middle of 2022.
Read MoreMay 10, 2021
Arthrosi’s New Molecule AR882 for Gout Shows Blockbuster-Potential
Our mission is to eliminate the pain of gout with a new era of gout treatment that provides a true solution.
Read More